

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

RESOLUTIONS PASSED AT THE 8TH BOARD MEETING FOR FY2026

The board of directors (the “Board”) and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

On 4 September 2026, the Company duly convened its 8th Board meeting for the financial year ending 31 December 2026 (“FY2026”) via teleconference. The meeting was held in compliance with the applicable Company Law and Securities Law, as well as the Articles of Association of the Company. The following resolutions were duly passed at the meeting:

1. That the proposed appointment of Mr. Chen Hong (陈洪) as General Manager of the Company be approved.

Mr. Chen Hong, born in August 1970, is a citizen of the People's Republic of China and holds a Bachelor of Medicine degree from Nanjing Medical University and an Executive MBA degree from Cheung Kong Graduate School of Business. From April 2011 to June 2025, Mr. Chen successively held senior management positions as Executive Deputy General Manager of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Co., Ltd. (广州白云山和记黄埔中药有限公司), General Manager and legal representative of Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co., Ltd. (国药控股和记黄埔医药(上海)有限公司),¹ General Manager of Hutchison Healthcare Limited (和黄健宝保健品有限公司), General Manager of Guangzhou Hutchison Hain Organic Co., Ltd. (广州和黄汉优有机产品有限公司), and Senior Vice President, Executive Vice President and Chief Commercial Officer (China) of HUTCHMED Group. From July 2025 to January 2026, Mr. Chen served as Deputy General Manager of Tianjin Tianyao Pharmaceutical Co., Ltd. (津药药业股份有限公司). Since January 2026, Mr. Chen has served as the Executive Deputy General Manager of the Company.

The proposed appointment of Mr. Chen Hong as General Manager of the Company has been considered and approved by the Nomination Committee of the Company.

2. That the proposed amendments to the Articles of Association of the Company and the application for changes in the industrial and commercial registration be approved.

Please refer to the Company's separate announcement entitled “*Proposed Amendments to the Articles of Association of the Company and Application for Changes in the Industrial and Commercial Registration*” released on the same date as this announcement for further details.

¹ Now known as Shanghai Hutchison Whampoa Pharmaceutical Sales Limited (上海和记黄埔医药销售有限公司).

3. That, pursuant to the applicable Company Law and the Articles of Association of the Company, the proposed convening of the 2nd extraordinary general meeting of the Company in 2026 (the “**2026 2nd EGM**”) be approved.

Resolution 2 above shall be submitted for shareholders' approval at the 2026 2nd EGM, notice of which will be issued in due course.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
4 September 2026